newsfilter
← Latest News
Business Wire·

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June